Scarica l'app Stockscreener
3.39
3.97%
-0.14
Dopo l'orario di chiusura:
3.40
0.010
+0.29%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARDX Giù?
Forum
Previsione
Precedente Chiudi:
$3.53
Aprire:
$3.52
Volume 24 ore:
5.08M
Relative Volume:
1.02
Capitalizzazione di mercato:
$945.06M
Reddito:
$251.85M
Utile/perdita netta:
$-72.58M
Rapporto P/E:
-10.82
EPS:
-0.3134
Flusso di cassa netto:
$-63.80M
1 W Prestazione:
-14.18%
1M Prestazione:
-23.99%
6M Prestazione:
-24.67%
1 anno Prestazione:
-57.73%
Intervallo 1D:
$3.35
$3.55
Intervallo di 1 settimana:
$3.35
$3.95
Portata 52W:
$3.35
$8.1391
Ardelyx Inc Stock (ARDX) Company Profile
Nome
Ardelyx Inc
Settore
Industria
Telefono
510-745-7047
Indirizzo
34175 ARDENWOOD BLVD., FREMONT, CA
Confronta ARDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
3.39 | 945.06M | 251.85M | -72.58M | -63.80M | -0.3134 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-02 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-03-07 | Ripresa | Ladenburg Thalmann | Buy |
| 2025-03-04 | Iniziato | BTIG Research | Buy |
| 2024-11-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-07-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-04-05 | Iniziato | Leerink Partners | Outperform |
| 2023-12-18 | Iniziato | Raymond James | Strong Buy |
| 2023-09-07 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-25 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2023-03-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2022-11-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-05-06 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-12-01 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2021-10-14 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2021-07-21 | Downgrade | Jefferies | Buy → Hold |
| 2021-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-03-23 | Iniziato | Wedbush | Outperform |
| 2021-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-20 | Ripresa | Citigroup | Buy |
| 2020-02-18 | Ripresa | Jefferies | Buy |
| 2020-02-12 | Iniziato | Citigroup | Buy |
| 2020-02-10 | Iniziato | Cowen | Outperform |
| 2019-04-08 | Iniziato | Piper Jaffray | Overweight |
| 2018-08-24 | Iniziato | Jefferies | Buy |
| 2018-03-19 | Ripresa | Leerink Partners | Outperform |
| 2017-11-29 | Reiterato | Citigroup | Buy |
| 2017-11-22 | Reiterato | Ladenburg Thalmann | Buy |
| 2017-10-17 | Ripresa | Leerink Partners | Outperform |
| 2016-03-31 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-03-09 | Iniziato | Cantor Fitzgerald | Buy |
| 2016-03-03 | Iniziato | Citigroup | Buy |
Mostra tutto
Ardelyx Inc Borsa (ARDX) Ultime notizie
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - Bluefield Daily Telegraph
Investors Who Lost Money on Ardelyx, Inc. Should Contact Levi & Korsinsky About an Ongoing InvestigationARDX - ACCESS Newswire
Investors who Lost Money on Ardelyx, Inc. Should Contact Levi & Korsinsky About an Ongoing InvestigationARDX - ACCESS Newswire
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Ardelyx, Inc. (ARDX) - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 15, 2024 in Ardelyx LawsuitARDX - ACCESS Newswire
Ardelyx, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Ardelyx, Inc. (ARDX) - ACCESS Newswire
David Mott Bought 19% More Shares In Ardelyx - simplywall.st
Shareholders that lost money on Ardelyx, Inc.(ARDX) should contact Levi & Korsinsky about pending Class ActionARDX - ACCESS Newswire
Ardelyx, Inc. Class Action: Levi & Korsinsky Reminds Ardelyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 15, 2024ARDX - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of Ardelyx, Inc.(ARDX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Investors who lost money on Ardelyx, Inc.(ARDX) should contact Levi & Korsinsky about pending Class ActionARDX - ACCESS Newswire
Shareholders that lost money on Ardelyx, Inc. (ARDX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Ardelyx, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationARDX - ACCESS Newswire
ARDX LAWSUIT ALERT: Levi & Korsinsky Notifies Ardelyx, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Reminds Ardelyx, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 15, 2024ARDX - ACCESS Newswire
Ardelyx, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your RightsARDX - ACCESS Newswire
(ARDX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Ardelyx downgraded at Raymond James after Q1 sales miss - MSN
Ardelyx presents data supporting IBSRELA at DDW 2025 - TipRanks
Ardelyx First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Hedge Fund and Insider Trading News: Paul Tudor Jones, Warren Buffett, John Paulson Bill Ackman, Platinum Asset Management, Ardelyx Inc (ARDX), Stem Inc (STEM), and More - Insider Monkey
Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digesti - GuruFocus
Ardelyx (ARDX) Highlights IBSRELA's Efficacy at Digestive Diseas - GuruFocus
Ardelyx (ARDX) Highlights IBSRELA's Efficacy at Digestive Disease Week Conference | ARDX Stock News - GuruFocus
Ardelyx showcases IBSRELA data at Digestive Disease Week - Investing.com Australia
Ardelyx showcases IBSRELA data at Digestive Disease Week By Investing.com - Investing.com South Africa
Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference - TradingView
Triple Study Results: IBSRELA IBS-C Drug Proves Safe for Teens and Nursing Mothers at DDW 2025 - Stock Titan
Shareholders that lost money on Ardelyx, Inc.(ARDX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Ardelyx, Inc. (NASDAQ:ARDX) Q1 2025 Earnings Call Transcript - Insider Monkey
Ardelyx Inc Reports Strong Growth Amid Challenges - MSN
Ardelyx targets $240M-$250M in IBSRELA 2025 sales amid strong Q1 growth - MSN
Analysts Have Been Trimming Their Ardelyx, Inc. (NASDAQ:ARDX) Price Target After Its Latest Report - Yahoo Finance
Raymond James cuts Ardelyx stock rating, lowers target to $11 By Investing.com - Investing.com Canada
Ardelyx (ARDX) Price Target Lowered by Citigroup to $10.00 | ARDX Stock News - GuruFocus
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Ardelyx, Inc.(ARDX) Shareholders - ACCESS Newswire
Ardelyx Inc earnings missed by $0.06, revenue fell short of estimates - Investing.com Australia
Raymond James cuts Ardelyx stock rating, lowers target to $11 - Investing.com Australia
Ardelyx (ARDX) Faces Downgrade Amid Revenue Shortfall - GuruFocus
Ardelyx's Q1 Loss Widens; Shares Fall - marketscreener.com
Ardelyx stock downgraded at Raymond James (ARDX:NASDAQ) - Seeking Alpha
Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty (NASDAQ:ARDX) - Seeking Alpha
Stocks in play: SECURE Waste Infrastructure Corp. - The Globe and Mail
Block, Atlassian, Apple, Roku, Amazon And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Raymond James Downgrades Ardelyx to Outperform From Strong Buy, Adjusts Price Target to $11 From $13 - marketscreener.com
Ardelyx (ARDX) Downgraded by Raymond James Amid Sales Concerns | - GuruFocus
Ardelyx (ARDX) Price Target Reduced by Citi After Q1 Report | AR - GuruFocus
Ardelyx (ARDX) Downgraded by Raymond James Amid Sales Concerns | ARDX Stock News - GuruFocus
Ardelyx (ARDX) Price Target Reduced by Citi After Q1 Report | ARDX Stock News - GuruFocus
Why Twilio Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Shareholders of Ardelyx, Inc. Should Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your RightsARDX - ACCESS Newswire
Ardelyx Inc Azioni (ARDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):